• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

P0304 SARS-COV-2 in Colorectal Cancer of IBD Patients - Oxford Academic

Mary Wilson

Well-known member
2025 European Crohn's and Colitis Organisation (ECCO) Published by Oxford​

Published: 22 January 2025​

https://doi.org/10.1093/ecco-jcc/jjae190.0478

M M Boscá Watts, S Navarro, S Rosello, J M Varela, S Gonzalez, U Fernández, A Sanahuja, C Mongort, T García, C Suria, J Tosca, R Antón, V Merino, M Ponce, R Villagrasa, V Pla, D Moro, D Casado, D Navarro, I Pascual​

Abstract

Background
It has been hypothesized that inflammation related to SARS-CoV-2 infection can affect cancer cell proliferation, without having a direct oncogenic effect. SARS-CoV-2 infection is associated with the ACE2 receptor. ACE-2 over-expression has been found in many kinds of malignancies, including rectum adenocarcinoma (ADC) and in IBD patients. IBD-associated CRC (colorectal cancer) arises from a specific carcinogenic pathway involving chronic inflammation which is distinct from the traditional pathways.

IBD patients characteristically had right colon cancer and a higher incidence with respect to the general population, which had declined over time.

Methods
We observed a sudden increase in CRC incidence. Between June 2022 and May 2024, 6 of our patients presented with ano-rectal cancer (4 in the lower rectum and two in the anal canal). Biopsies were reviewed as usual and an extra study searching for coronavirus protein was also performed. Immunohistochemical analysis was performed using OMNIS Automated System (AGILENT), and monoclonal antibody anti-SARS-COV-2 clone 1A9 from Gene Tex. Inc (USA) at 1:100. All patients had signed consent.

Results
They were male, ages 38-62, one smoked and one was an ex-smoker, duration of the disease 3-31 years, two were overweight. 3 Crohn’s Disease (CD) and 3 Ulcerative Colitis (UC). CD: A3L1B2, A2L2B1 and A1L3B3p. UC: 2 extensive and one distal. All on different treatments: adalimumab and azathioprine, azathioprine and steroids, filgotinib, two were on vedolizumab and one was only on oral mesalamine (never biologics). 5/6 were in endoscopical remission. They were diagnosed of ADC of distal rectum and two of perianal ADC. Four of them were mucinous ADC (including the two perianal ones), one conventional low grade infiltrant ADC (pT1) in distal rectum-anus, and the sixth with rectal intramucous ADC. 100% had received COVID vaccines (variable type) and had had COVID infections. Biopsies: all frequent viruses were negative, whereas coronavirus was found in all cases, with a diffuse cytoplasmic and granular pattern. See figures 1 and 2.

Conclusion
The incidence of CRC in our patients in the past two years is relevant. The type of tumour and its locations also calls our attention, as well as the fact that all tumours have SARS-COV-2 protein abundance. Whether an epiphenomenom, part of the cause or a trigger for CRC of this specific type, will have to be dilucidated in prospective studies. We do not know if coronavirus stays longer in the bowel mucosae of our IBD patients (long covid) or maybe just in a subpopulation. It is of clinical relevance no matter whether the coronavirus is a mere spectator or an actor. Many questions arise with just these six patients, which we hope to answer in the future.

https://academic.oup.com/ecco-jcc/article/19/Supplement_1/i757/7967367?login=false
 
Back
Top Bottom